SOPHiA GENETICS (SOPH) CLO sells 684 shares for tax obligations

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Legal Officer Daan Van Well sold 684 ordinary shares in an open-market transaction at a weighted average price of $4.7865 per share, within a $4.69–$4.87 range. The sale was made under a pre-established Rule 10b5-1 plan solely to cover tax obligations from restricted stock vesting. Following this tax-related sale, Van Well directly holds 261,238 ordinary shares.

Insider Trade Summary 10b5-1

Net Seller: 684 shares ($3,274)

Net Sell 1 txn

Insider Van Well Daan

Role Chief Legal Officer

Sold 684 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	684	$4.7865	$3K

Holdings After Transaction: Ordinary Shares — 261,238 shares (Direct)

Footnotes (1)

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on March 18, 2026. The sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.69 to $4.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Van Well Daan

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/19/2026		S		684(1)	D	$4.7865(2)	261,238	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on March 18, 2026. The sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.69 to $4.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-Fact for Daan van Well	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did SOPHiA GENETICS (SOPH) disclose in this Form 4 for Daan Van Well?

The filing shows Chief Legal Officer Daan Van Well sold 684 SOPHiA GENETICS ordinary shares. This open-market transaction was tied to tax obligations from restricted stock unit vesting and executed under a pre-established Rule 10b5-1 trading plan.

How many SOPHiA GENETICS (SOPH) shares did Daan Van Well sell and at what price?

Daan Van Well sold 684 ordinary shares of SOPHiA GENETICS. The weighted average sale price reported was $4.7865 per share, with individual trades executed in a price range between $4.69 and $4.87 per share.

Why did Daan Van Well sell SOPHiA GENETICS (SOPH) shares in this transaction?

The shares were sold to satisfy tax obligations arising from the vesting of restricted stock units on March 18, 2026. This makes the sale compensation-related rather than a discretionary decision to change overall investment exposure.

Was the SOPHiA GENETICS (SOPH) insider sale by Daan Van Well discretionary?

The sale was not discretionary. It was carried out under a pre-established Rule 10b5-1 trading plan adopted by Daan Van Well, meaning the trades were pre-arranged and executed automatically according to preset instructions.

How many SOPHiA GENETICS (SOPH) shares does Daan Van Well hold after this Form 4 sale?

After selling 684 ordinary shares, Daan Van Well directly holds 261,238 SOPHiA GENETICS shares. This indicates the reported sale represents a very small portion of his total direct holdings in the company.

What does the price range in the SOPHiA GENETICS (SOPH) Form 4 sale indicate?

The filing notes the reported price is a weighted average, with trades occurring between $4.69 and $4.87. This means multiple small transactions executed within that range, collectively averaging $4.7865 per share for the 684 shares sold.